Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293794927> ?p ?o ?g. }
Showing items 1 to 63 of
63
with 100 items per page.
- W4293794927 endingPage "32" @default.
- W4293794927 startingPage "22" @default.
- W4293794927 abstract "Singapore is one of the most rapidly ageing societies in the world. Currently, Singapore ranks first in the world for the incidence of diabetes-induced end-stage renal disease (ESRD) and seventh for the incidence of kidney failures per million population. It is estimated that nearly one-quarter of Singapore’s population will have chronic kidney disease (CKD) by 2035. Disease management of CKD has been identified as a critical issue due to the rapid increase in cases among the elderly in recent years. Chronic kidney disease is associated with adverse clinical outcomes, and metabolic complications such as anaemia, cardiovascular events, and CKD-associated metabolic bone diseases present treatment management complexities to healthcare professionals. Early detection and management of CKD can avert complications before symptoms occur and prevent the progressive loss of kidney function over time. Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) are recommended for hypertension and proteinuria management in CKD patients with and without diabetes. However, neither of these agents alone reduces the risk of all-cause mortality; furthermore, combinational therapy of ACEI plus ARB is associated with renal dysfunction, stroke, and/or hyperkalaemia. Recently, the use of sodium–glucose cotransporter 2 inhibitors (SGLT2i) has been shown to provide favourable effects on the kidney and cardiovascular outcomes in patients with or without type 2 diabetes mellitus. Studies have shown that early initiation of SGLT2i may slow or halt the progression of CKD in patients with the risk of CKD and ESRD. This review discusses the mechanisms underlying the progression of CKD, its associated risk factors and summarises the management strategies as per Kidney Disease Outcomes Quality Initiative clinical practice guideline recommendations. This article also summarises the evidence regarding the use of SGLT2i in slowing the progression of CKD and improvement of health-related quality of life." @default.
- W4293794927 created "2022-08-31" @default.
- W4293794927 creator A5062107602 @default.
- W4293794927 date "2022-05-01" @default.
- W4293794927 modified "2023-10-14" @default.
- W4293794927 title "Complications of Chronic Kidney Disease: Therapeutic Approaches and What Can Be Done to Halt Disease Progression?" @default.
- W4293794927 doi "https://doi.org/10.33591/sfp.48.5.u3" @default.
- W4293794927 hasPublicationYear "2022" @default.
- W4293794927 type Work @default.
- W4293794927 citedByCount "0" @default.
- W4293794927 crossrefType "journal-article" @default.
- W4293794927 hasAuthorship W4293794927A5062107602 @default.
- W4293794927 hasBestOaLocation W42937949271 @default.
- W4293794927 hasConcept C120665830 @default.
- W4293794927 hasConcept C121332964 @default.
- W4293794927 hasConcept C126322002 @default.
- W4293794927 hasConcept C134018914 @default.
- W4293794927 hasConcept C159641895 @default.
- W4293794927 hasConcept C177713679 @default.
- W4293794927 hasConcept C2778653478 @default.
- W4293794927 hasConcept C2779134260 @default.
- W4293794927 hasConcept C2779561371 @default.
- W4293794927 hasConcept C2780091579 @default.
- W4293794927 hasConcept C2908647359 @default.
- W4293794927 hasConcept C555293320 @default.
- W4293794927 hasConcept C61511704 @default.
- W4293794927 hasConcept C71924100 @default.
- W4293794927 hasConcept C99454951 @default.
- W4293794927 hasConceptScore W4293794927C120665830 @default.
- W4293794927 hasConceptScore W4293794927C121332964 @default.
- W4293794927 hasConceptScore W4293794927C126322002 @default.
- W4293794927 hasConceptScore W4293794927C134018914 @default.
- W4293794927 hasConceptScore W4293794927C159641895 @default.
- W4293794927 hasConceptScore W4293794927C177713679 @default.
- W4293794927 hasConceptScore W4293794927C2778653478 @default.
- W4293794927 hasConceptScore W4293794927C2779134260 @default.
- W4293794927 hasConceptScore W4293794927C2779561371 @default.
- W4293794927 hasConceptScore W4293794927C2780091579 @default.
- W4293794927 hasConceptScore W4293794927C2908647359 @default.
- W4293794927 hasConceptScore W4293794927C555293320 @default.
- W4293794927 hasConceptScore W4293794927C61511704 @default.
- W4293794927 hasConceptScore W4293794927C71924100 @default.
- W4293794927 hasConceptScore W4293794927C99454951 @default.
- W4293794927 hasIssue "5" @default.
- W4293794927 hasLocation W42937949271 @default.
- W4293794927 hasOpenAccess W4293794927 @default.
- W4293794927 hasPrimaryLocation W42937949271 @default.
- W4293794927 hasRelatedWork W1975155164 @default.
- W4293794927 hasRelatedWork W2021055445 @default.
- W4293794927 hasRelatedWork W2112172095 @default.
- W4293794927 hasRelatedWork W2289481372 @default.
- W4293794927 hasRelatedWork W2908822532 @default.
- W4293794927 hasRelatedWork W2970908922 @default.
- W4293794927 hasRelatedWork W2998175073 @default.
- W4293794927 hasRelatedWork W4240837265 @default.
- W4293794927 hasRelatedWork W4307047478 @default.
- W4293794927 hasRelatedWork W2398505927 @default.
- W4293794927 hasVolume "48" @default.
- W4293794927 isParatext "false" @default.
- W4293794927 isRetracted "false" @default.
- W4293794927 workType "article" @default.